Sonnenborn, U. Escherichia coli strain Nissle 1917-from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties. FEMS Microbiol. Lett. 363 , 1–6 (2016). INTRODUCTION. Escherichia coli Nissle was one of the first strains used as a probiotic (reviewed in reference 1).It was isolated in 1917 from a German soldier who remained healthy while his comrades succumbed to infections caused by Shigella. Background and purpose: Escherichia coli Nissle 1917 is a probiotic strain used in the treatment of intestinal immune diseases, including ulcerative colitis. The aim of the present study was to test if this probiotic bacterium can also show systemic immunomodulatory properties after oral administration. Clinical effectiveness and dose dependency of E. coli Nissle (EcN) enemas were investigated in ulcerative colitis (UC). Methods: In a double-blind study, 90 patients with moderate distal activity in UC were randomly assigned to treatment with either 40, 20, or 10 ml enemas (N = 24, 23, 23) containing 10E8 EcN/ml or placebo (N = 20). Here we aimed to investigate whether E. coli Nissle regulates gammadelta T cell function, thereby linking the innate and adaptive immune system. In our study, we demonstrate that, in contrast to the other probiotic strains tested, E. coli Nissle increased activation, cell cycling and expansion of gammadelta, but not alphabeta T cells. The aim of the current study was therefore to investigate the antimicrobial and antibiofilm activities of a range of bacteria including organisms isolated from human skin, and the candidate probiotic E. coli Nissle 1917. E. coli Nissle 1917 is a commonly studied candidate probiotic bacterium. Probiotic bacteria like E. coli Nissle 1917 (EcN), Lactobacillus species, Streptococcus species, and Bifidobacterium species work to boost the immune system either individually or in combination with other probiotic strains. Probiotics biofilm presence in a healthy gut promotes nutrient exchange between the host and microbiota, and it increases Probiotics are able to attenuate intestinal inflammation due to its immunomodulatory properties, being considered as safe when chronically administered. The aim was to test the association of minocycline, a tetracycline with immunomodulatory properties, and the probiotic Escherichia coli Nissle 1917 (EcN) in a mouse model of reactivated colitis. Probiotics are viable non-pathogenic microorganisms that confer health benefits to the host by improving the microbial balance of the indigenous microflora. 9 Apart from anecdotal experience, two controlled studies with the probiotic bacterial strain Escherichia coli Nissle 1917 (EcN) in UC already exist. 10, 11 These trials showed no We genetically engineer Escherichia coli Nissle 1917 (EcN) to create fibrous matrices that promote gut epithelial integrity in situ. These matrices consist of curli nanofibers displaying trefoil factors (TFFs), known to promote intestinal barrier function and epithelial restitution. We confirm that engineered EcN can secrete the curli-fused 6LDr.